These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18616639)

  • 1. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.
    Lorente A; Mueller W; Urdangarín E; Lázcoz P; Lass U; von Deimling A; Castresana JS
    Brain Pathol; 2009 Apr; 19(2):279-92. PubMed ID: 18616639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
    Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
    Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR.
    Lorente A; Mueller W; Urdangarín E; Lázcoz P; von Deimling A; Castresana JS
    BMC Cancer; 2008 Feb; 8():61. PubMed ID: 18298842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
    Gömöri E; Pál J; Kovács B; Dóczi T
    Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
    Christmann M; Nagel G; Horn S; Krahn U; Wiewrodt D; Sommer C; Kaina B
    Int J Cancer; 2010 Nov; 127(9):2106-18. PubMed ID: 20131314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.
    Piperi C; Themistocleous MS; Papavassiliou GA; Farmaki E; Levidou G; Korkolopoulou P; Adamopoulos C; Papavassiliou AG
    Mol Med; 2010; 16(1-2):1-9. PubMed ID: 19809523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
    Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF
    BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
    Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
    CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation analysis of APC, AXIN2, DACT1, RASSF1A and MGMT gene promoters in non-small cell lung cancer.
    Paschidis K; Zougros A; Chatziandreou I; Tsikalakis S; Korkolopoulou P; Kavantzas N; Saetta AA
    Pathol Res Pract; 2022 Jun; 234():153899. PubMed ID: 35489124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.